🧠 Food for thought

Implications, context, and why it matters.

Automated lab infrastructure attracts mega-rounds despite unproven commercial returns

• Lila Sciences raised $435 million total in just over a year, moving from a $200 million seed round in March to a $235 million Series A at a $1.23 billion valuation1.
• The company’s “AI science factories” model, combining automated labs with AI-driven research, represents a significant infrastructure bet that investors are willing to make before seeing commercial products.
• Despite claiming to have “discovered thousands of novel proteins, nucleic acids, chemistries and materials,” Lila hasn’t commercialized any products yet1.
• Investor Daniel Adamson described Lila as an “IP factory par excellence,” suggesting investors are betting on patent generation rather than immediate product sales1.
• This trend reflects broader AI biotech funding trends, where startups raised $10.5 billion across 511 deals in 2024, often based on platform potential rather than proven therapeutics2.

Plummeting biotech costs create opportunities for AI-driven experimentation at scale

• The cost of sequencing a human genome dropped from $3 billion in 2001 to approximately $1,000 today, making large-scale biological data generation economically feasible3.
• Biotech processes that previously took months can now be completed in under an hour, creating conditions where AI can process and act on biological data much faster3.
• Lila’s approach of creating feedback loops between AI models and physical experimentation becomes viable when lab automation costs have decreased significantly.
• The company’s CEO Geoffrey von Maltzahn noted that relying solely on “publicly available data” hits a ceiling, making proprietary experimental data generation essential for competitive advantage1.
• This shift toward automated experimentation parallels developments at companies like Ginkgo Bioworks, which use automated robots to rapidly produce and analyze biological data4.

Update: (September 16, 9:30 a.m. SGT): This article was updated to correct that Lila Sciences is an AI science company, not a biotechnology firm. Bloomberg initially referred to the latter version of description.